Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
… findings highlight the need for combination therapies, such as bempedoic acid, to optimize lipid management and achieve NICE targets in prima…
….31 discounted QALYs at a lifetime cost of 166,513 units, while bempedoic acid yielded 11.01 discounted QALYs at 389,310 units. Compared with …
…. cData missing for 14 patients.BA, bempedoic acid; BA+EZE-FDC. Bempedoic acid/ezetimibe fixed-dose combination; HeFH, heterozygous familial h…
… bempedoic acid, and 2% received a combination of Ezetimibe and bempedoic acid. No patients were initiated on PCSK9 inhibitors.Abstract 7-007 …
…ntion populations.2 This analysis assesses the effectiveness of bempedoic acid, a non-statin lipid-lowering therapy, in achieving NICE non-HDL…
…th the greatest reductions in LDL-C, followed by inclisiran and bempedoic acid.…
…h individual and combination LLT, including statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors. Admission lipid profile and pre-ACS LLT …
…arget (111) Off target (197) Both groups (308) Statin% 95 85 89 Atorvastatin Total Number% 62 61 62 Mean Dose (mg) 57.71 (SD 25.03) 58.33 (S…
…rotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors or bempedoic acid. Recent studies suggest that N=1-interventions may help disting…
…s with hypercholesterolaemia treated with PCSK9i (alirocumab or evolocumab).To assess the acceptance rate of the interventions.Material an…
…isease, and three with familial hypercholesterolaemia. Prior to inclisiran, 11 patients (28.9%) had been treated with evolocumab and 2 pat…
…-lowering agents (ezetimibe 4.1%, PCSK9 inhibitor 0.4%, none on bempedoic acid).Conclusions Notable gaps exist in statin prescribing and LDL g…